Table 4.
Selected ongoing and now-recruiting clinical trials of novel anti-TAA inhibitors in B cell malignancies.
| Drug | Class | Disease Setting | Phase | Study | References |
|---|---|---|---|---|---|
| Belantamab mafodotin/ GSK2857916 |
ADC anti-BCMA-monomethyl auristatin F |
R/R MM | I/II I/II |
NCT03848845 Active, 2018- Alone or combined with pembrolizumab NCT04126200 NCT03544281 NCT03715478 Recruiting, 2018- Alone or combined with current therapies |
[273] |
| Teclistamab/ JNJ-64007957 |
BiTE anti-BCMA/CD3 | R/R MM | I/II I III |
NCT04557098 Active, 2017–2024 NCT04586426 Recruiting, 2019–2024 Combined with talquetamab or daratumuab or pomalidomide NCT05083169 Recruiting, 2021–2026 daratumumab compared with current therapies |
[278] |
| Elranatamab/ PF-06863135 |
BiTE anti-BCMA/CD3 | Refractory MM | II |
NCT04649359 Active, 2020–2024 |
|
| Idecabtagene vicleucel/ bb2121 |
Anti-BCMA CAR-T | R/R MM | II |
NCT03361748 Active, 2017–2024 |
[279] |
| BM38 | Dual anti-BCMA/CD38 CAR-T | R/R MM | I | ChiCTR1900026286 Active, 2019- |
[281] |
| BCMA-CAR-NK92 | Anti-BCMA CAR-NK | R/R MM | I/II |
NCT03940833 Recruiting, 2019–2022 |
[282] |
| Lanalumab/VAY-736 | Anti-BAFF-R Ab | CLL | I |
NCT03400176, Recruiting, 2018- Alone or combined with ibrutinib |
|
| BAFFR-CAR T | Anti-BAFF-R CAR-T | B-ALL, R/R MCL | I |
NCT04690595, NCT05370430 Recruiting, 2020–2024 |
|
| Cirmtuzumab/ UC961 newly renamed Zilovertamab |
Anti-ROR1 Ab | CLL CLL, SLL, MCL R/R MCL |
II I/II III |
NCT04501939 Recruiting, 2020- Combined with venetoclax NCT03088878 Active, 2018–2025 Combined with ibrutinib NCT05431179 Recruiting, 2022- Combined with ibrutinib |
|
| Pembrolizumab/MK-3475 | Anti-PD1 Ab recruiting immune cells to attack tumor B cells | R/R CLL, B-NHL | II |
NCT02332980 Active, 2015–2023 Alone or combined with ibrutinib or idelalisib |
[283] |
| High-Risk or R/R CLL/SLL | II |
NCT03204188 Active, 2017–2030 Combined with ibrutinib, fludarabine |
|||
| R/R WM | II |
NCT03630042 Recruiting, 2018- Combined with rituximab |
|||
| R/R B-ALL | I/II |
NCT03512405 Recruiting, 2018- Combined with blinatumomab |
[284] | ||
| R/R DLBCL | I |
NCT03340766 Active, 2017- Combined with blinatumomab |
|||
| Cemiplimab/ REGN2810 |
Anti-PD1 Ab recruiting immune cells to attack tumor B cells |
B-NHL R/R MM DLBCL |
I I/II I/II |
NCT02651662 Active, 2016- Combined with REGN1979 (anti-CD20-CD3) NCT03194867 Active, 2016- Combined with isatuximab NCT03769181 Active, 2018- Combined with isatuximab |
[285] |
| Atezolizumab | Anti-PD-L1 Ab | DLBCL | I/II |
NCT02926833 Active, 2016–2022 Alone or combined with axicabtagene ciloleucel |
[286] |
| Ulocuplumab/ BMS-936564 |
Anti-CXCR4 Ab | WM | I/II |
NCT03225716 Active, 2017–2025 Alone or combined with ibrutinib |
[287] |
| Mavorixafor/ AMD070 |
CXCR4 antagonist (blocks CXCL12 binding) | WM | I |
NCT04274738 Active, 2020–2025 Alone or combined with ibrutinib |
|
| CS1-CAR-T | CS1-CAR-T/IL7- CCL19 |
R/R MM | I |
NCT03778346 Recruiting, 2018–2022 |
|
| CS1-CAR-T | CS1-CAR-T/41BB- tEGFR |
R/R MM | I |
NCT03710421 Recruiting, 2018–2023 following chemotherapy |
|
| J1/Melflufen | Melphalan-p-fluoro-L-phenylalalnine (aminopeptidase substrat) | MM refractory to lenalidomide | III |
NCT03151811 Active, 2017- combined with dexamethasone compared to pomalidomide + dexamethasone |
[288] |
| Brentuximab vedotin | ADC anti-CD30-mono methyl auristatin E | R/R B-NHL | II |
NCT03646123 Active, 2018–2026 |
|
| Lilotomab/ tetulomab/ betalutin |
ARC anti-CD37-177lutetium | Relapsed B-NHL | I/II |
NCT01796171 Recruiting, 2013–2026 |
[289] |
| GEN3009 | DuoHexaBody-CD37 | R/R B-NHL | I |
NCT04358458 Recruiting, 2020–2025 |
|
| CART30 | Anti-CD30 CAR-T | B-NHL | I |
NCT02259556 Recruiting, 2016–2029 Combined with cyclophosphamide and fludarabine |
[290] |
| CD30.CAR-Ts | Anti-CD30 CAR-T | B-NHL | I/II |
NCT02690545 Recruiting, 2016–2038 Combined with fludarabine and bendamustine |
[291] |
| CD30.CAR T | Anti-CD30 CAR-T | B-NHL | I |
NCT02917083 Recruiting, 2018–2036 |
|
| ICAR30 | Anti-CD30 CAR-T | B-NHL | I |
NCT03383965 Recruiting, 2017–2025 |
|
| ATLCAR.CD30 | Anti-CD30 CAR-T | B-NHL | I | NCT026663297 Active, 2016–2037 |
|
| Magrolimab/ Hu5F9-G4 |
Anti-CD47 |
R/R B-NHL | I/II |
NCT02953509 Active, 2016–2026 Combined with rituximab and (in some cases) with chemotherapy |
[292] |
| R/R MM | II |
NCT04892446 Recruiting, 2021–2024 Combined with daratumumab, or pomalidomide and dexamethasone, or bortezomib and dexamethasone |
|||
| R/R B-NHL | II |
NCT04788043 Recruiting, 2021–2027 Combined with pembrolizumab |
|||
| IBI322 | Bi anti-CD47/PD-L1 | ALL, CLL/SLL B-NHL | I |
NCT04795128 Recruiting, 2021–2024 |
|
| TG-1801/ NI-1701 |
Bi anti-CD47/CD19 | B-NHL B-NHL, CLL |
I Ib |
NCT03804996 Active, 2019–2022 Combined with ublituximab NCT04806035 Recruiting, 2021–2023 Alone or combined with ublituximab |
[293] |
| CPO107/ JMT601 |
Fusion protein Anti-CD20-SIRPα | Advanced B-NHL |
I |
NCT04853329 Recruiting, 2021–2024 |
|
| STRO-001 | ADC anti-CD74- maytansoid |
DLBCL, FL, MM | I |
NCT03424603 Recruiting, 2018–2023 |
[294] |
| Polatuzumab vedotin | ADC anti-CD79b-monomethyl auristatin E | DLBCL | I |
NCT04231877 Recruiting, 2020–2031 Combined with rituximab, prednisone, etoposide, doxorubicin, cyclophosphamide |
|
| R/R DLBCL | I |
NCT04739813 Recruiting, 2021–2027 Combined with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide |
|||
| R/R B-NHL | Ib/II |
NCT03533283 Recruiting, 2018–2024 Combined with glofitamab |
|||
| Cevostomab/ BFCR4350A |
BiTE-anti-FcRL5/CD3 | R/R MM | I |
NCT03275103 Recruiting, 2017–2023 |
[295] |
| Talquetamab/ JNJ-64407564 |
BiTE duoBody-anti-GPRC5D/CD3 | R/R MM | I/II |
NCT03399799 Recruiting, 2018–2025 |
[296] |
ADAM17, a disintegrin and metalloprotease 17; ADC, antibody drug conjugate; BAFF-R, B-cell activating factor receptor; BCMA, B cell maturation antigen FcRL5, Fc receptor-like 5; GPRC5D, G-protein coupled receptor family C group 5 member D; ROR1, receptor tyrosine kinase-like orphan receptor 1; tEGFR, truncated epidermal growth factor receptor.